On March 9, 2021, Advarra announced its acquisition of Bio-Optronics, maker of CCTrialSuite, which includes the leading clinical trial management system (CTMS) Clinical Conductor, as well as the Momentum clinical workforce scheduling application and Biopoint patient workflow software. You can read the full press release here.
We will continue to conduct business as usual, and clients will keep their current team for support, customer relationships, and implementation projects. Advarra and Bio-Optronics clients will continue to receive the high level of quality service that they have come to expect, while gaining access to the enhanced benefits the combined company will provide.
We understand that questions may arise as we bring our organizations together, so we’ve assembled this FAQ to address some of the most commonly asked questions about the Bio-Optronics acquisition. If you don’t see your question addressed here, please contact your Bio-Optronics Customer Success Manager or the Advarra Customer Relationships Team at email@example.com.
Q: How will the acquisition impact our working relationship with Bio-Optronics and Advarra?
A: Our clients and their seamless use of our technology remain top priority. We will maintain diligent adherence to the quality of our work, personalized client support, implementation projects, and turnaround times. We have assembled a dedicated team to work on integration efforts, and we will conduct business as usual and minimize any impacts to our clients. Operational excellence will remain at the forefront of what we do.
We are committed to transparency and communicating any changes as we integrate. As such, we have put together a process and communication plan for managing updates to ensure you are informed in advance of any changes.
Q: How will this impact the Advarra and Bio-Optronics products I use today?
A: Advarra and Bio-Optronics remain committed to providing all of our customers with quality products to best support your needs and support research operations. Advarra will honor existing contracts without changes. Our teams are continuing with business as usual and are committed to maintaining a high level of support. Any changes as a result of the integration will be communicated to ensure the continuity of your research.
Q: How long do you expect integration will take?
A: Integration activities will take approximately six months. Any changes to policies and procedures that impact you will be proactively communicated.
Q: How will my interaction with Advarra and Bio-Optronics change?
A: We are committed to providing customers with the highest level of customer service. Please continue to work with your existing contacts at Bio-Optronics and Advarra. We will communicate and coordinate any changes in personnel assignments in advance.
Q: What will happen to my data?
A: There will be no changes to your data or use of technology. We consider data privacy a top priority and we will continue to treat your data in a protected and secure manner.
Q: Will there be any changes to existing contracts?
A: No. Advarra will continue to honor existing Bio-Optronics contracts without changes, and no changes are needed to Advarra contracts.
Q: Is the acquisition complete?
A: Yes. Advarra’s acquisition of Bio-Optronics was completed on March 3, 2021.